{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:25:14Z","timestamp":1773271514425,"version":"3.50.1"},"reference-count":74,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T00:00:00Z","timestamp":1428278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases grant","doi-asserted-by":"crossref","award":["P01DK056492"],"award-info":[{"award-number":["P01DK056492"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH","award":["5T32DK007732-20"],"award-info":[{"award-number":["5T32DK007732-20"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human immunodeficiency virus (<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>) infection and hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) infection affect populations worldwide. With the availability of over 35 Food and Drug Administration approved medications for treatment of<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>, the morbidity and mortality associated with<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>has greatly improved. On the other hand, treatment options for<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>have been limited until very recently. While the use of protease inhibitors (such as boceprevir and telaprevir) has become standard of care for treatment of hepatitis C in the general population, data for individuals with impaired kidney function, particularly those on dialysis, are extremely limited. Use of medications in dialysis patients can be challenging given the dose adjustments that must be made for renally cleared molecules, and potentially increased impact of adverse effects such as anemia. Recommendations for dosing of marketed therapies for<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>and<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>are reviewed.<\/jats:p>","DOI":"10.1111\/sdi.12367","type":"journal-article","created":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T03:58:43Z","timestamp":1428379123000},"page":"397-403","source":"Crossref","is-referenced-by-count":5,"title":["<scp>HIV<\/scp>and<scp>HCV<\/scp>Medications in End\u2010Stage Renal Disease"],"prefix":"10.1111","volume":"28","author":[{"given":"Keiko I.","family":"Greenberg","sequence":"first","affiliation":[{"name":"Department of Medicine The Johns Hopkins University School of Medicine Baltimore Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[{"name":"Section of Nephrology Department of Medicine Yale University School of Medicine New Haven Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed G.","family":"Atta","sequence":"additional","affiliation":[{"name":"Department of Medicine The Johns Hopkins University School of Medicine Baltimore Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2014.05.001"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60164-1"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.535518"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2005.18108.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu617"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"e_1_2_7_8_1","first-page":"9270","article-title":"Epidemiology and natural history of hepatitis C virus infection","volume":"20","author":"Lee MH","year":"2014","journal-title":"World J Gastroenterol"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000355615"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01607.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.4081\/idr.2013.s1.e7"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00040.2003"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0558"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.10.006"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2014.06.001"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000103"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00251-06"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986706778521931"},{"key":"e_1_2_7_20_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents:Guidelines for the Use of Antiretroviral Agents in HIV\u20101\u2010Infected Adults and Adolescents Department of Health and Human Services. Available athttp:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf accessed September 9 2014"},{"key":"e_1_2_7_21_1","unstructured":"Food and Drug Administation:Rescriptor Prescribing Information. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020705s018lbl.pdf accessed September 9 2014"},{"key":"e_1_2_7_22_1","unstructured":"Food and Drug Administration:Sustiva Prescribing Information. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020972s038lbl.pdf accessed September 9 2014"},{"key":"e_1_2_7_23_1","unstructured":"Food and Drug Administration:Intelence Prescribing Information. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022187s002lbl.pdf accessed September 9 2014"},{"key":"e_1_2_7_24_1","unstructured":"Food and Drug Administration:Viramune Prescribing Information. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/20636s025 20933s014lbl.pdf accessed September 9 2014"},{"key":"e_1_2_7_25_1","unstructured":"Food and Drug Administration:Edurant Prescribing Information. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204790lbl.pdf accessed September 9 2014"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00370705"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2009.08.014"},{"key":"e_1_2_7_28_1","unstructured":"Food and Drug Administration:Isentress Prescribing Information. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022145s004lbl.pdf accessed September 9 2014"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00363-10"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1590-9"},{"key":"e_1_2_7_31_1","unstructured":"Food and Drug Administration:Tivicay Prescribing Information. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204790lbl.pdf accessed September 9 2014"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1403-99"},{"key":"e_1_2_7_33_1","unstructured":"Food and Drug Administration:Selzentry Prescribing Information. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022128lbl.pdf accessed September 9 2014"},{"key":"e_1_2_7_34_1","unstructured":"Food and Drug Admministration:Fuzeon Prescribing Information. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021481s017lbl.pdf accessed September 9 2014"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31816237f0"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12276"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0142-5"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911303212203"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911303212204"},{"key":"e_1_2_7_40_1","unstructured":"Food and Drug Administration:Pegasys Precribing Information. Available athttp:\/\/www.fda.gov\/downloads\/drugs\/developmentapprovalprocess\/howdrugsaredevelopedandapproved\/approvalapplications\/therapeuticbiologicapplications\/ucm094462.pdf accessed September 9 2014"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127002237996"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.03.037"},{"key":"e_1_2_7_43_1","unstructured":"Food and Drug Administration:Labeling changes for Pegasys and Copegus re: dosing patients with renal impairment. Available athttp:\/\/www.fda.gov\/forconsumers\/byaudience\/forpatientadvocates\/ucm267594.htm accessed September 9 2014"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1137-x"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-11-201312030-00005"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.1.193"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307399"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v6.i5.326"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-013-0182-8"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.036996"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261935"},{"key":"e_1_2_7_52_1","volume-title":"ClinicalTrials.gov [Internet]","author":"Columbia University; Merck Sharp & Dohme Corp"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.10.009"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462414521164"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.05.008"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0153-9"},{"key":"e_1_2_7_57_1","unstructured":"Food and Drug Administration:Olysio Prescribing Information. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/205123s001lbl.pdf accessed September 9 2014"},{"key":"e_1_2_7_58_1","volume-title":"ClinicalTrials.gov","author":"Merck Sharp & Dohme Corp."},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014534194"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.775246"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X13515825"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61113-1"},{"key":"e_1_2_7_63_1","unstructured":"National Library of Medicine (US) Bethesda MD Gilead Sciences Sofosbuvir plus ribavirin in subjects with HCV infection and renal insufficiencyClinicalTrials.gov"},{"key":"e_1_2_7_64_1","volume-title":"ClinicalTrials.gov","author":"AbbVie"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/751057"},{"key":"e_1_2_7_66_1","unstructured":"Food and Drug Administration:Victrelis Prescribing Information. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202258lbl.pdf accessed September 9 2014"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis824"},{"key":"e_1_2_7_68_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","article-title":"Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial","volume":"159","author":"Sulkowski MS","year":"2013","journal-title":"Ann Intern Med"},{"key":"e_1_2_7_69_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/QCO.0b013e32835c2027","article-title":"Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct\u2010acting antiviral drugs in the HIV\u2010positive patient","volume":"26","author":"Rodriguez\u2010Torres M","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu675"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2008.08.009"},{"key":"e_1_2_7_72_1","first-page":"177","article-title":"Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function","volume":"60","author":"Murakami C","year":"2014","journal-title":"Minerva Gastroenterol Dietol"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1371007"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.03.020"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209026"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fsdi.12367","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sdi.12367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T23:25:08Z","timestamp":1747869908000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/sdi.12367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,6]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/sdi.12367"],"URL":"https:\/\/doi.org\/10.1111\/sdi.12367","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,6]]}}}